Sarcoma | Tumor

CURE’s sarcoma page features the latest cancer news and updates on sarcoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in sarcoma.

When it Comes to Sarcoma, Second Opinions Matter

February 25th 2016, 1:25pm

Article

Though Early, T-Cell Therapy Making Strides in Treatment of Sarcoma

February 11th 2016, 3:13am

Article

The breakthrough designation will expedite the development and review of this novel T-cell therapy in synovial sarcoma.

FDA Approves Halaven for Advanced Liposarcoma

January 29th 2016, 5:24am

Article

The approval of Halaven was based on an improvement in overall survival (OS) in a phase 3 study.

Adding New Agent to Chemotherapy Boosts Survival in Small Trial of Soft Tissue Sarcoma

November 13th 2015, 8:32pm

Article

Based on this study, the monoclonal antibody is being investigated in an ongoing phase 3 study and has received an FDA Breakthrough Therapy Designation.

FDA Approves Yondelis in Soft Tissue Sarcoma

October 23rd 2015, 6:40pm

Article

The approval is based on results from the phase 3 ET743-SAR-3007 trial.

Caregiver Challenge: Sharing Their Pain

June 20th 2015, 12:09am

Article

Caregivers may grapple with practical and emotional challenges as they help loved ones manage cancer-related pain.

Eribulin Extends Survival in Phase 3 Sarcoma Study

February 26th 2015, 9:05am

Article

Treatment with eribulin mesylate significantly extended overall survival (OS) compared with dacarbazine in patients with advanced soft tissue sarcoma, according to topline results from a phase 3 clinical trial.

Yondelis Receives Priority Review for Advanced Soft Tissue Sarcoma

February 4th 2015, 2:09am

Article

The Food and Drug Administration (FDA) granted a priority review to Yondelis to treat patients with the disease, including liposarcoma and leiomyosarcoma subtypes, who have previously received chemotherapy that included an anthracycline. The FDA will make its final approval decision within six months.

Several Cancer Therapies Up for FDA Review in 2015

January 13th 2015, 10:48pm

Article

The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

NORD Offers Information and Support for Patients of Rare Cancers

November 25th 2014, 2:57am

Article

NORD was founded in 1983 by parents of children with rare diseases. Over the past 30 years, it has become a powerful advocacy voice for all patients with rare diseases, including cancer.